Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas

Modern Pathology

Volumn 18, Issue 12, 2005, Pages 1599-1605

  Korja, Miikka ^a   Finne, Jukka ^a   Salmi, Toivo T ^b   Kalimo, Hannu ^b   Karikoski, Riitta ^c   Tanner, Minna ^c,d   Isola, Jorma ^d   Haapasalo, Hannu ^c  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGENIC SUBSTRATE; KI 67 ANTIGEN; MOLECULAR MARKER; MYC PROTEIN; NESTIN; PARAFFIN;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE AMPLIFICATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; NEUROBLAST; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SAMPLE; SOUTHERN BLOTTING; TUMOR;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CHROMOGENIC COMPOUNDS; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; INTERMEDIATE FILAMENT PROTEINS; KI-67 ANTIGEN; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 27944506469     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800462     Document Type: Article

References (21)

1. Schwab M, Westermann F, Hero B, et al. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-480 (Review).
2. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-248.
3. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2699-2708.
4. Krams M, Hero B, Berthold F, et al. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer 2002;94:854-861.
5. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1997;15:1171-1182.
6. Shimada H, Chatten J, Newton Jr WA, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-416.
7. Ambros PF, Ambros IM, Kerbl R, et al. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med Pediatr Oncol 2001;36:1-4.
8. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.
9. Lasorella A, Boldrini R, Dominici C, et al. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 2002;62:301-306.
10. Wang Q, Hii G, Shusterman S, et al. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res 2003;63:1631-1635.
11. Vandesompele J, Edsjo A, De Preter K, et al. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Oncogene 2003;22:456-460.
12. Thomas SK, Messam CA, Spengler BA, et al. Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 2004;279:27994-27999.
13. Ahdevaara P, Kalimo H, Torma T, et al. Differentiating intracerebral neuroblastoma: report of a case and review of the literature. Cancer 1977;40:784-788.
14. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastomas: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-363.
15. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
16. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994;174:275-282.
17. Rummukainen JK, Salminen T, Lundin J, et al. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001;81:1545-1551.
18. Shapiro DN, Valentine MB, Rowe ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol 1993;142:1339-1346.
19. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.
20. Valent A, Le Roux G, Barrois M, et al. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. J Pathol 2002;198:495-501.
21. Rudolph P, Lappe T, Hero B, et al. Prognostic significance of the proliferative activity in neuroblastoma. Am J Pathol 1997;150:133-145.